Test Code ALBLI Limited Bleeding Diathesis Profile Interpretation
Specimen Required
Useful For
Interpretation of testing performed as part of a profile to detect of the more common potential causes of abnormal bleeding (eg, factor deficiencies/hemophilia, von Willebrand disease, factor-specific inhibitors) and a simple screen to evaluate for an inhibitor or severe deficiency of factor XIII (rare)
This test is not useful for assessing platelet function (eg, congenital or acquired disorders such as Glanzmann thrombasthenia, Bernard-Soulier syndrome, storage pool disease, myeloproliferative disease, associated platelet dysfunction), which requires fresh platelets
Method Name
Only orderable as part of a profile. For more information see ALBLD / Bleeding Diathesis Profile, Limited, Plasma.
Medical Interpretation
Reporting Name
Limited Bleed Prof InterpSpecimen Type
Plasma Na CitSpecimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Frozen | 14 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Clinical Information
Bleeding problems may be associated with a wide variety of coagulation abnormalities or may be due to problems not associated with coagulation (trauma and surgery as obvious examples). A partial listing of causes follows.
-Deficiency or functional abnormality (congenital or acquired) of any of the following coagulation proteins: fibrinogen (factor I), factor II (prothrombin), factor V, factor VII, factor VIII (hemophilia A), factor IX (hemophilia B), factor X, factor XI (hemophilia C; bleeding severity not always proportionate to factor level), factor XIII (fibrin-stabilizing factor), von Willebrand factor (VWF antigen and activity), and alpha-2 plasmin inhibitor and plasminogen activator inhibitor (PAI-I; severe deficiency in rare cases). Neither alpha-2 plasmin inhibitor nor PAI-I are included as a routine bleeding diathesis assay component, but either can be performed if indicated or requested.
-Deficiency (thrombocytopenia) or functional abnormality of platelets such as congenital (eg, Glanzmann thrombasthenia, Bernard-Soulier syndrome, storage pool disorders) and acquired (eg, myeloproliferative disorders, uremia, drugs) disorders. Platelet function abnormalities cannot be studied on mailed-in specimens.
-Specific factor inhibitors (most commonly directed against factor VIII); factor inhibitors occur in 10% to15% of the hemophilia population and are more commonly associated with severe deficiencies of factor VIII or IX (antigen <1%). The inhibitor appears in response to transfusion therapy with factor concentrates with no correlation of occurrence and amount of therapy. Factor VIII inhibitors may occur spontaneously in the postpartum patient, with certain malignancies, in association with autoimmune disorders (eg, rheumatoid arthritis, systemic lupus erythematosus), in the elderly, and for no apparent reason.
-Other acquired causes of increased bleeding include paraproteinemia; other factor-specific inhibitors, including those against factor V, factor XI; or virtually any of the coagulation proteins.
-Acute disseminated intravascular coagulation/intravascular coagulation and fibrinolysis (DIC/ICF), which is a fairly common cause of bleeding. Bleeding can also occur in patients with chronic ICF.
Reference Values
Only orderable as part of a profile. For more information see ALBLD / Bleeding Diathesis Profile, Limited, Plasma.
An interpretive report will be provided.
Interpretation
An interpretive report will be provided when testing is completed, noting a presence or absence of a bleeding diathesis disease state.
Cautions
Patient should not be receiving Coumadin or heparin. If the patient is currently on warfarin or heparin, this should be noted, as warfarin or heparin therapy can affect certain coagulation factors or assays, preclude their performance, or cause spurious results. Patient should also not be receiving fibrinolytic agents (streptokinase, urokinase, tissue plasminogen activator: tPA).
If patient has been recently transfused, this should be noted; it is best to perform this study pretransfusion, if possible.
Day(s) Performed
Monday through Friday
Report Available
7 to 21 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
Not ApplicableCPT Code Information
85390-26 Special Coagulation Interpretation
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
ALBLI | Limited Bleed Prof Interp | 69049-5 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
603322 | Reviewed by | 18771-6 |
603181 | Limited Bleed Prof Interp | 69049-5 |